title: Acute myelogenous leukemia in elderly patients not eligible for intensive chemotherapy: the dark side of the moon.
abstract: BACKGROUND
  Acute Myelogenous Leukemia (AML) is a common disease in people aged>60 years. About 50% of the patients are not eligible for aggressive chemotherapy (CT) and are only managed with conservative approaches. Results in this subset of patients have not been reported so far.
  
  
  METHODS
  We retrospectively evaluated 244 consecutive elderly AML patients (M/F 143/101, median age 72 years, range 60-90) diagnosed at our institution from January 1989 to December 1998 and not eligible for intensive CT. Eighty-nine patients (36.5%) had evolved from previous myelodysplasia (sAML). Fifty-three out of 192 (26.4%) patients with available bone marrow (BM) analysis had oligoblastic leukaemia (blasts<40% and WBC<15x10(9)/l).
  
  
  RESULTS
  Sixty-seven patients (27.5%) were managed with supportive treatment only. One hundred seventy-seven patients (72.5%), in order to control disease, received conservative CT, consisting of Hydroxyurea (HU) (127 patients, 71.7%), Cytarabine and 6-Thioguanine (39 patients, 22%) or low-dose cytarabine (11 patients, 6.3%). Median overall survival was 179 days (1-3278) with 50 patients (20.5%) surviving>12 months. Older age (>75 years), poor WHO PS (>2), lower PLT levels (<50x10(9)/l) and higher absolute peripheral blast count (>5x10(9)/l) showed a negative prognostic impact on survival in multivariate analysis.
  
  
  CONCLUSIONS
  Our data outline the great heterogeneity of elderly AML patients not eligible for intensive CT. A simple scoring system including easily evaluable parameters, which could distinguish subjects with different prognosis, is proposed. Moreover, randomized studies in order to establish best conservative approaches are warranted.
authors.affiliation: Dipartimento di Biotecnologie Cellulari ed Ematologia, Universita La Sapienza di Roma, Ematologia, Ospedale S. Giovanni, Roma, Ematologia, Istituto Regina Elena, Roma, Italy. rob.lati@libero.it
authors.forename: R
authors.initials: R
authors.lastname: Latagliata
authors.forename: V
authors.initials: V
authors.lastname: Bongarzoni
authors.forename: I
authors.initials: I
authors.lastname: Carmosino
authors.forename: A
authors.initials: A
authors.lastname: Mengarelli
authors.forename: M
authors.initials: M
authors.lastname: Breccia
authors.forename: P A
authors.initials: PA
authors.lastname: Borza
authors.forename: M
authors.initials: M
authors.lastname: D'Andrea
authors.forename: G M
authors.initials: GM
authors.lastname: D'Elia
authors.forename: S
authors.initials: S
authors.lastname: Mecarocci
authors.forename: S G
authors.initials: SG
authors.lastname: Morano
authors.forename: M C
authors.initials: MC
authors.lastname: Petti
authors.forename: F
authors.initials: F
authors.lastname: Mandelli
authors.forename: G
authors.initials: G
authors.lastname: Alimena
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D005260:Female; D006299:Health Services for the Aged; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D011788:Quality of Life; D012189:Retrospective Studies; D016019:Survival Analysis; D013866:Thioguanine / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D003561:Cytarabine; D013866:Thioguanine; D006918:Hydroxyurea